Carlo Baraldi

Modena, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Evidence-based guidelines for the pharmacological treatment of migraine.

Evidence-based guidelines for the pharmacological treatment of migraine.

Journal: Cephalalgia : an international journal of headache
Published: April 25, 2025

Evidence-based guidelines for the pharmacological treatment of migraine, summary version.

Evidence-based guidelines for the pharmacological treatment of migraine, summary version.

Journal: Cephalalgia : an international journal of headache
Published: April 25, 2025

Fremanezumab for the Treatment of Migraine Complicated by Medication Overuse: A Systematic Review.

Fremanezumab for the Treatment of Migraine Complicated by Medication Overuse: A Systematic Review.

Journal: Clinical drug investigation
Published: March 02, 2025

The preclinical discovery and development of atogepant for migraine prophylaxis.

The preclinical discovery and development of atogepant for migraine prophylaxis.

Journal: Expert opinion on drug discovery
Published: June 10, 2024

Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study.

Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: January 29, 2024

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.

Journal: CNS drugs
Published: October 25, 2023

Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study.

Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: August 29, 2023

Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study.

Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study.

Journal: Acta neurologica Belgica
Published: July 22, 2023

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.

Journal: Journal of neurology
Published: May 07, 2023

Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).

Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: February 19, 2023

OnabotulinumtoxinA: Still the Present for Chronic Migraine.

OnabotulinumtoxinA: Still the Present for Chronic Migraine.

Journal: Toxins
Published: December 02, 2022

Melanocortin receptor agonist NDP-α-MSH improves cognitive deficits and microgliosis but not amyloidosis in advanced stages of AD progression in 5XFAD and 3xTg mice.

Melanocortin receptor agonist NDP-α-MSH improves cognitive deficits and microgliosis but not amyloidosis in advanced stages of AD progression in 5XFAD and 3xTg mice.

Journal: Frontiers in immunology
Published: October 27, 2022
Showing 1-12 of 54

Last Updated: 09/26/2026